Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 64 entries
Sorted by: Best Match Show Resources per page
Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors.

Experimental and therapeutic medicine

Wu C, Gui C, Li L, Pang Y, Tang Z, Wei J.
PMID: 29545886
Exp Ther Med. 2018 Apr;15(4):3577-3581. doi: 10.3892/etm.2018.5811. Epub 2018 Jan 30.

Neuregulin-1 (NRG-1) is a positive regulator of angiogenesis, which suggests there may be an association between NRG-1 and angiogenic factors. The aim of the present study was to investigate the effect of treating human cardiac microvascular endothelial cells (HCMECs)...

Cite
Wu C, Gui C, Li L, et al. Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors. Exp Ther Med. 2018;15(4):3577-3581doi: 10.3892/etm.2018.5811.
Wu, C., Gui, C., Li, L., Pang, Y., Tang, Z., & Wei, J. (2018). Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors. Experimental and therapeutic medicine, 15(4), 3577-3581. https://doi.org/10.3892/etm.2018.5811
Wu, Chengqiang, et al. "Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors." Experimental and therapeutic medicine vol. 15,4 (2018): 3577-3581. doi: https://doi.org/10.3892/etm.2018.5811
Wu C, Gui C, Li L, Pang Y, Tang Z, Wei J. Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors. Exp Ther Med. 2018 Apr;15(4):3577-3581. doi: 10.3892/etm.2018.5811. Epub 2018 Jan 30. PMID: 29545886; PMCID: PMC5840939.
Copy Download .nbib Format: NLM
Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.

Biologics : targets & therapy

Henson ES, Johnston JB, Los M, Gibson SB.
PMID: 19707333
Biologics. 2007 Sep;1(3):229-39.

The epidermal growth factor (EGF) receptors play an important role in epithelial cell function. Upon stimulation of these receptors, an extensive network of signal transduction pathways is activated, including the PI3K/AKT and Ras/Erk pathways. This activation leads to cellular...

Cite
Henson ES, Johnston JB, Los M, et al. Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics. 2007;1(3):229-39
Henson, E. S., Johnston, J. B., Los, M., & Gibson, S. B. (2007). Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics : targets & therapy, 1(3), 229-39.
Henson, Elizabeth S, et al. "Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer." Biologics : targets & therapy vol. 1,3 (2007): 229-39.
Henson ES, Johnston JB, Los M, Gibson SB. Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer. Biologics. 2007 Sep;1(3):229-39. PMID: 19707333; PMCID: PMC2721308.
Copy Download .nbib Format: NLM
ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease.

Frontiers in cellular neuroscience

Iwakura Y, Nawa H.
PMID: 23408472
Front Cell Neurosci. 2013 Feb 13;7:4. doi: 10.3389/fncel.2013.00004. eCollection 2013.

Ligands for ErbB1-4 receptor tyrosine kinases, such as epidermal growth factor (EGF) and neuregulins, regulate brain development and function. Thus, abnormalities in their signaling are implicated in the etiology or pathology of schizophrenia and Parkinson's disease. Among the ErbB...

Cite
Iwakura Y, Nawa H. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Front Cell Neurosci. 2013;7:4doi: 10.3389/fncel.2013.00004.
Iwakura, Y., & Nawa, H. (2013). ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Frontiers in cellular neuroscience, 74. https://doi.org/10.3389/fncel.2013.00004
Iwakura, Yuriko, and Nawa, Hiroyuki. "ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease." Frontiers in cellular neuroscience vol. 7 (2013): 4. doi: https://doi.org/10.3389/fncel.2013.00004
Iwakura Y, Nawa H. ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Front Cell Neurosci. 2013 Feb 13;7:4. doi: 10.3389/fncel.2013.00004. eCollection 2013. PMID: 23408472; PMCID: PMC3570895.
Copy Download .nbib Format: NLM
A role for ErbB signaling in the induction of reactive astrogliosis.

Cell discovery

Chen J, He W, Hu X, Shen Y, Cao J, Wei Z, Luan Y, He L, Jiang F, Tao Y.
PMID: 29238610
Cell Discov. 2017 Dec 05;3:17044. doi: 10.1038/celldisc.2017.44. eCollection 2017.

Reactive astrogliosis is a hallmark of many neurological disorders, yet its functions and molecular mechanisms remain elusive. Particularly, the upstream signaling that regulates pathological responses of astrocytes is largely undetermined. We used a mouse traumatic brain injury model to...

Cite
Chen J, He W, Hu X, et al. A role for ErbB signaling in the induction of reactive astrogliosis. Cell Discov. 2017;3:17044doi: 10.1038/celldisc.2017.44.
Chen, J., He, W., Hu, X., Shen, Y., Cao, J., Wei, Z., Luan, Y., He, L., Jiang, F., & Tao, Y. (2017). A role for ErbB signaling in the induction of reactive astrogliosis. Cell discovery, 317044. https://doi.org/10.1038/celldisc.2017.44
Chen, Jing, et al. "A role for ErbB signaling in the induction of reactive astrogliosis." Cell discovery vol. 3 (2017): 17044. doi: https://doi.org/10.1038/celldisc.2017.44
Chen J, He W, Hu X, Shen Y, Cao J, Wei Z, Luan Y, He L, Jiang F, Tao Y. A role for ErbB signaling in the induction of reactive astrogliosis. Cell Discov. 2017 Dec 05;3:17044. doi: 10.1038/celldisc.2017.44. eCollection 2017. PMID: 29238610; PMCID: PMC5717352.
Copy Download .nbib Format: NLM
HER3 Is an Actionable Target in Advanced Prostate Cancer.

Cancer research

Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J.
PMID: 34753775
Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 09.

It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 protein is commonly...

Cite
Gil V, Miranda S, Riisnaes R, et al. HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res. 2021;81(24):6207-6218doi: 10.1158/0008-5472.CAN-21-3360.
Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D'Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., Sharp, A., Sheehan, B., Christova, R., Seed, G., Figueiredo, I., Lambros, M., Dolling, D., Rekowski, J., Alajati, A., Clarke, M., Pereira, R., Flohr, P., Fowler, G., Boysen, G., Sumanasuriya, S., Bianchini, D., Rescigno, P., Aversa, C., Tunariu, N., Guo, C., Paschalis, A., Bertan, C., Buroni, L., Ning, J., Carreira, S., Workman, P., Swain, A., Califano, A., Shen, M. M., Alimonti, A., Neeb, A., Welti, J., Yuan, W., de Bono, J. (2021). HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer research, 81(24), 6207-6218. https://doi.org/10.1158/0008-5472.CAN-21-3360
Gil, Veronica, et al. "HER3 Is an Actionable Target in Advanced Prostate Cancer." Cancer research vol. 81,24 (2021): 6207-6218. doi: https://doi.org/10.1158/0008-5472.CAN-21-3360
Gil V, Miranda S, Riisnaes R, Gurel B, D'Ambrosio M, Vasciaveo A, Crespo M, Ferreira A, Brina D, Troiani M, Sharp A, Sheehan B, Christova R, Seed G, Figueiredo I, Lambros M, Dolling D, Rekowski J, Alajati A, Clarke M, Pereira R, Flohr P, Fowler G, Boysen G, Sumanasuriya S, Bianchini D, Rescigno P, Aversa C, Tunariu N, Guo C, Paschalis A, Bertan C, Buroni L, Ning J, Carreira S, Workman P, Swain A, Califano A, Shen MM, Alimonti A, Neeb A, Welti J, Yuan W, de Bono J. HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Res. 2021 Dec 15;81(24):6207-6218. doi: 10.1158/0008-5472.CAN-21-3360. Epub 2021 Nov 09. PMID: 34753775.
Copy Download .nbib Format: NLM
Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer.

Journal of applied biomedicine

Molavi G, Samadi N, Hashemzadeh S, Halimi M, Hosseingholi EZ.
PMID: 34907725
J Appl Biomed. 2020 Aug;18(2):46-53. doi: 10.32725/jab.2020.008. Epub 2020 Jun 17.

Breast cancer is the most common malignancy among females worldwide. Recent studies have shown extra-ribosomal roles of the moonlight ribosomal proteins in the development of human cancers. Accurate quantification of the gene expression level is based on the selection...

Cite
Molavi G, Samadi N, Hashemzadeh S, et al. Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer. J Appl Biomed. 2020;18(2):46-53doi: 10.32725/jab.2020.008.
Molavi, G., Samadi, N., Hashemzadeh, S., Halimi, M., & Hosseingholi, E. Z. (2020). Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer. Journal of applied biomedicine, 18(2), 46-53. https://doi.org/10.32725/jab.2020.008
Molavi, Ghader, et al. "Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer." Journal of applied biomedicine vol. 18,2 (2020): 46-53. doi: https://doi.org/10.32725/jab.2020.008
Molavi G, Samadi N, Hashemzadeh S, Halimi M, Hosseingholi EZ. Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer. J Appl Biomed. 2020 Aug;18(2):46-53. doi: 10.32725/jab.2020.008. Epub 2020 Jun 17. PMID: 34907725.
Copy Download .nbib Format: NLM
Aberrant epithelial polarity cues drive the development of precancerous airway lesions.

Proceedings of the National Academy of Sciences of the United States of America

Tilston-Lunel A, Mazzilli S, Kingston NM, Szymaniak AD, Hicks-Berthet J, Kern JG, Abo K, Reid ME, Perdomo C, Wilson AA, Spira A, Beane J, Varelas X.
PMID: 33903236
Proc Natl Acad Sci U S A. 2021 May 04;118(18). doi: 10.1073/pnas.2019282118.

Molecular events that drive the development of precancerous lesions in the bronchial epithelium, which are precursors of lung squamous cell carcinoma (LUSC), are poorly understood. We demonstrate that disruption of epithelial cellular polarity, via the conditional deletion of the...

Cite
Tilston-Lunel A, Mazzilli S, Kingston NM, et al. Aberrant epithelial polarity cues drive the development of precancerous airway lesions. Proc Natl Acad Sci U S A. 2021;118(18)doi: 10.1073/pnas.2019282118.
Tilston-Lunel, A., Mazzilli, S., Kingston, N. M., Szymaniak, A. D., Hicks-Berthet, J., Kern, J. G., Abo, K., Reid, M. E., Perdomo, C., Wilson, A. A., Spira, A., Beane, J., & Varelas, X. (2021). Aberrant epithelial polarity cues drive the development of precancerous airway lesions. Proceedings of the National Academy of Sciences of the United States of America, 118(18), . https://doi.org/10.1073/pnas.2019282118
Tilston-Lunel, Andrew, et al. "Aberrant epithelial polarity cues drive the development of precancerous airway lesions." Proceedings of the National Academy of Sciences of the United States of America vol. 118,18 (2021). doi: https://doi.org/10.1073/pnas.2019282118
Tilston-Lunel A, Mazzilli S, Kingston NM, Szymaniak AD, Hicks-Berthet J, Kern JG, Abo K, Reid ME, Perdomo C, Wilson AA, Spira A, Beane J, Varelas X. Aberrant epithelial polarity cues drive the development of precancerous airway lesions. Proc Natl Acad Sci U S A. 2021 May 04;118(18). doi: 10.1073/pnas.2019282118. PMID: 33903236; PMCID: PMC8106308.
Copy Download .nbib Format: NLM
Betacellulin-Induced α-Cell Proliferation Is Mediated by ErbB3 and ErbB4, and May Contribute to β-Cell Regeneration.

Frontiers in cell and developmental biology

Lee YS, Song GJ, Jun HS.
PMID: 33553143
Front Cell Dev Biol. 2021 Jan 21;8:605110. doi: 10.3389/fcell.2020.605110. eCollection 2020.

Betacellulin (BTC), an epidermal growth factor family, is known to promote β-cell regeneration. Recently, pancreatic α-cells have been highlighted as a source of new β-cells. We investigated the effect of BTC on α-cells. Insulin+glucagon+ double stained bihormonal cell levels...

Cite
Lee YS, Song GJ, Jun HS. Betacellulin-Induced α-Cell Proliferation Is Mediated by ErbB3 and ErbB4, and May Contribute to β-Cell Regeneration. Front Cell Dev Biol. 2021;8:605110doi: 10.3389/fcell.2020.605110.
Lee, Y. S., Song, G. J., & Jun, H. S. (2020). Betacellulin-Induced α-Cell Proliferation Is Mediated by ErbB3 and ErbB4, and May Contribute to β-Cell Regeneration. Frontiers in cell and developmental biology, 8605110. https://doi.org/10.3389/fcell.2020.605110
Lee, Young-Sun, et al. "Betacellulin-Induced α-Cell Proliferation Is Mediated by ErbB3 and ErbB4, and May Contribute to β-Cell Regeneration." Frontiers in cell and developmental biology vol. 8 (2020): 605110. doi: https://doi.org/10.3389/fcell.2020.605110
Lee YS, Song GJ, Jun HS. Betacellulin-Induced α-Cell Proliferation Is Mediated by ErbB3 and ErbB4, and May Contribute to β-Cell Regeneration. Front Cell Dev Biol. 2021 Jan 21;8:605110. doi: 10.3389/fcell.2020.605110. eCollection 2020. PMID: 33553143; PMCID: PMC7859283.
Copy Download .nbib Format: NLM
p52Shc regulates the sustainability of ERK activation in a RAF-independent manner.

Molecular biology of the cell

Yoshizawa R, Umeki N, Yamamoto A, Okada M, Murata M, Sako Y.
PMID: 34260260
Mol Biol Cell. 2021 Sep 01;32(19):1838-1848. doi: 10.1091/mbc.E21-01-0007. Epub 2021 Jul 14.

p52SHC (SHC) and GRB2 are adaptor proteins involved in the RAS/MAPK (ERK) pathway mediating signals from cell-surface receptors to various cytoplasmic proteins. To further examine their roles in signal transduction, we studied the translocation of fluorescently labeled SHC and...

Cite
Yoshizawa R, Umeki N, Yamamoto A, et al. p52Shc regulates the sustainability of ERK activation in a RAF-independent manner. Mol Biol Cell. 2021;32(19):1838-1848doi: 10.1091/mbc.E21-01-0007.
Yoshizawa, R., Umeki, N., Yamamoto, A., Okada, M., Murata, M., & Sako, Y. (2021). p52Shc regulates the sustainability of ERK activation in a RAF-independent manner. Molecular biology of the cell, 32(19), 1838-1848. https://doi.org/10.1091/mbc.E21-01-0007
Yoshizawa, Ryo, et al. "p52Shc regulates the sustainability of ERK activation in a RAF-independent manner." Molecular biology of the cell vol. 32,19 (2021): 1838-1848. doi: https://doi.org/10.1091/mbc.E21-01-0007
Yoshizawa R, Umeki N, Yamamoto A, Okada M, Murata M, Sako Y. p52Shc regulates the sustainability of ERK activation in a RAF-independent manner. Mol Biol Cell. 2021 Sep 01;32(19):1838-1848. doi: 10.1091/mbc.E21-01-0007. Epub 2021 Jul 14. PMID: 34260260; PMCID: PMC8684710.
Copy Download .nbib Format: NLM
Vale Colin Ward-A Leader in Receptor Structural Biology.

Frontiers in endocrinology

Lawrence MC, Colman PM.
PMID: 28553260
Front Endocrinol (Lausanne). 2017 May 11;8:95. doi: 10.3389/fendo.2017.00095. eCollection 2017.

No abstract available.

Cite
Lawrence MC, Colman PM. Vale Colin Ward-A Leader in Receptor Structural Biology. Front Endocrinol (Lausanne). 2017;8:95doi: 10.3389/fendo.2017.00095.
Lawrence, M. C., & Colman, P. M. (2017). Vale Colin Ward-A Leader in Receptor Structural Biology. Frontiers in endocrinology, 895. https://doi.org/10.3389/fendo.2017.00095
Lawrence, Michael C, and Colman, Peter M. "Vale Colin Ward-A Leader in Receptor Structural Biology." Frontiers in endocrinology vol. 8 (2017): 95. doi: https://doi.org/10.3389/fendo.2017.00095
Lawrence MC, Colman PM. Vale Colin Ward-A Leader in Receptor Structural Biology. Front Endocrinol (Lausanne). 2017 May 11;8:95. doi: 10.3389/fendo.2017.00095. eCollection 2017. PMID: 28553260; PMCID: PMC5425603.
Copy Download .nbib Format: NLM
Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma.

Oncology letters

Chen T, Zhou L, Li H, Tian Y, Li J, Dong L, Zhao Y, Wei D.
PMID: 29113229
Oncol Lett. 2017 Nov;14(5):5934-5946. doi: 10.3892/ol.2017.6954. Epub 2017 Sep 15.

The aim of the present study was to investigate changes in the expression of ErbBs during epithelial-mesenchymal transition (EMT) of breast cancer cells and its association with the expression of fatty acid synthase (FASN). MCF-7-MEK5 cells were used as...

Cite
Chen T, Zhou L, Li H, et al. Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma. Oncol Lett. 2017;14(5):5934-5946doi: 10.3892/ol.2017.6954.
Chen, T., Zhou, L., Li, H., Tian, Y., Li, J., Dong, L., Zhao, Y., & Wei, D. (2017). Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma. Oncology letters, 14(5), 5934-5946. https://doi.org/10.3892/ol.2017.6954
Chen, Tingting, et al. "Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma." Oncology letters vol. 14,5 (2017): 5934-5946. doi: https://doi.org/10.3892/ol.2017.6954
Chen T, Zhou L, Li H, Tian Y, Li J, Dong L, Zhao Y, Wei D. Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma. Oncol Lett. 2017 Nov;14(5):5934-5946. doi: 10.3892/ol.2017.6954. Epub 2017 Sep 15. PMID: 29113229; PMCID: PMC5661422.
Copy Download .nbib Format: NLM
Chimeric mouse models for lung adenocarcinomas.

Future oncology (London, England)

Chen YR.
PMID: 20528228
Future Oncol. 2010 Jun;6(6):901-3. doi: 10.2217/fon.10.63.

Evaluation of: Zhou Y, Rideout WM 3rd, Zi T et al.: Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat. Biotechnol. 28(1), 71-78 (2010). EGFR and KRAS mutations are among the...

Cite
Chen YR. Chimeric mouse models for lung adenocarcinomas. Future Oncol. 2010;6(6):901-3doi: 10.2217/fon.10.63.
Chen, Y. R. (2010). Chimeric mouse models for lung adenocarcinomas. Future oncology (London, England), 6(6), 901-3. https://doi.org/10.2217/fon.10.63
Chen, Yi-Rong. "Chimeric mouse models for lung adenocarcinomas." Future oncology (London, England) vol. 6,6 (2010): 901-3. doi: https://doi.org/10.2217/fon.10.63
Chen YR. Chimeric mouse models for lung adenocarcinomas. Future Oncol. 2010 Jun;6(6):901-3. doi: 10.2217/fon.10.63. PMID: 20528228.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 64 entries